EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent advances in Camptothecin-derived antibody-drug conjugates

Xianqiang Yu, Dingyan Yu, Ye Wang, Biao Jiang, Hongli Chen

Bioorganic & Medicinal Chemistry · 2026

DOI: 10.1016/j.bmc.2026.118737 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic & Medicinal Chemistry, 2026. Verfasst von Xianqiang Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; School of Physical Science and Technology, S…. Hauptthemen laut MEDLINE: Camptothecin, Immunoconjugates, Antineoplastic Agents, Topoisomerase I Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: ShanghaiTech University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) represent a major advance in precision cancer therapy by combining the high target specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads through chemical linkers. Among the payload classes topoisomerase I (Topo I) inhibitors, camptothecin and its derivatives have emerged as highly promising warheads owing to their distinct mechanism of action and strong antitumor activity. The clinical success of Enhertu and Trodelvy, which employ the camptothecin-derived payloads DXd and SN-38, respectively, has validated the therapeutic potential of camptothecin-based ADCs and accelerated the development of next-generation candidates. This review summarizes recent progress in camptothecin-based ADCs since 2021, with a focus on strategies for payload modification of camptothecin derivatives, and linker optimization. In addition, current limitations of camptothecin-based ADCs, including resistance and insufficient efficacy, are discussed together with emerging solutions such as combination strategies and dual-payload ADCs. This review is expected to provide a useful framework for the rational design and further development of camptothecin-based ADCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CamptothecinImmunoconjugatesAntineoplastic AgentsTopoisomerase I InhibitorsNeoplasmsHumansAnimalsMolecular Structure

Stichwörter der Autor:innen

Antibody-drug conjugatesCamptothecinCombinationDual-payload

Substanzen

CamptothecinImmunoconjugatesAntineoplastic AgentsTopoisomerase I Inhibitors

Autor:innen und Institutionen

  • Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; School of Physical Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  • Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  • Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China. Electronic address: jiangbiao@shanghaitech.edu.cn.
  • Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China. Electronic address: chenhl@shanghaitech.edu.cn.

Förderung

  • ShanghaiTech University

Zitieren

APA

Yu, X., Yu, D., Wang, Y., Jiang, B., & Chen, H. (2026). Recent advances in Camptothecin-derived antibody-drug conjugates. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2026.118737

Vancouver

Yu X, Yu D, Wang Y, Jiang B, Chen H. Recent advances in Camptothecin-derived antibody-drug conjugates. Bioorganic & Medicinal Chemistry. 2026. doi:10.1016/j.bmc.2026.118737

BibTeX
@article{Yu2026,
  author = {Yu, Xianqiang and Yu, Dingyan and Wang, Ye and Jiang, Biao and Chen, Hongli},
  title = {Recent advances in Camptothecin-derived antibody-drug conjugates},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2026},
  doi = {10.1016/j.bmc.2026.118737}
}
Kostenlos starten →